Immunovant Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
23.05
-0.35
(-1.5%)
Volume:
1,192,798
52 week range:
22.41 - 39.55
Market Cap:
3.383B
Company Description:
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.